About Ventyx Biosciences
Ventyx Biosciences is a company based in Encinitas (United States) founded in 2018 by Raju Mohan was acquired by Lilly in January 2026.. Ventyx Biosciences has raised $165.3 million across 4 funding rounds from investors including Lilly, Sanofi and Orbimed. The company has 82 employees as of December 31, 2024. Ventyx Biosciences offers products and services including VTX2735, VTX3232, Tamuzimod, and VTX958. Ventyx Biosciences operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Horizon Therapeutics and Ultragenyx, among others.
- Headquarter Encinitas, United States
- Employees 82 as on 31 Dec, 2024
- Founders Raju Mohan
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ventyx Biosciences, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-135.12 M29.97as on Dec 31, 2024
-
EBITDA
$-146.8 M28.23as on Dec 31, 2024
-
Total Equity Funding
$165.3 M (USD)
in 4 rounds
-
Latest Funding Round
$27 M (USD), Post-IPO
Sep 23, 2024
-
Investors
Lilly
& 15 more
-
Employee Count
82
as on Dec 31, 2024
-
Acquired by
Lilly
(Jan 07, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Ventyx Biosciences
Ventyx Biosciences is a publicly listed company on the NASDAQ with ticker symbol VTYX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Ventyx Biosciences
Ventyx Biosciences offers a comprehensive portfolio of products and services, including VTX2735, VTX3232, Tamuzimod, and VTX958. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Peripherally restricted inhibitor for treating recurrent pericarditis.
CNS-penetrant inhibitor for neurodegenerative and cardiometabolic diseases.
Modulator for inflammatory bowel disease management.
Inhibitor for inflammatory bowel disease treatment.
Unlock access to complete
Unlock access to complete
Leadership Team
24 people
Product Management Team
8 people
Software Development Team
5 people
Advisor Team
4 people
Finance and Accounting
3 people
Data Analysis and Operations Team
2 people
Clinical Team
2 people
Chair Team
1 people
Unlock access to complete
Funding Insights of Ventyx Biosciences
Ventyx Biosciences has successfully raised a total of $165.3M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $27 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $27.0M
-
First Round
First Round
(09 Mar 2021)
- Investors Count 15
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2024 | Amount | Post-IPO - Ventyx Biosciences | Valuation |
investors |
|
| Sep, 2022 | Amount | Post-IPO - Ventyx Biosciences | Valuation |
investors |
|
| Sep, 2021 | Amount | Series B - Ventyx Biosciences | Valuation | VenBio , Third Point |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ventyx Biosciences
Ventyx Biosciences has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Sanofi and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A life sciences investment firm focused on novel therapeutics is operated.
|
Founded Year | Domain | Location | |
|
Life Sciences focused VC firm investing in the US
|
Founded Year | Domain | Location | |
|
Multiple sectors are targeted for venture capital investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ventyx Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ventyx Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ventyx Biosciences Comparisons
Competitors of Ventyx Biosciences
Ventyx Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Horizon Therapeutics and Ultragenyx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ventyx Biosciences
Frequently Asked Questions about Ventyx Biosciences
When was Ventyx Biosciences founded?
Ventyx Biosciences was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Where is Ventyx Biosciences located?
Ventyx Biosciences is headquartered in Encinitas, United States. It is registered at Encinitas, California, United States.
Who is the current CEO of Ventyx Biosciences?
Raju Mohan is the current CEO of Ventyx Biosciences. They have also founded this company.
Is Ventyx Biosciences a funded company?
Ventyx Biosciences is a funded company, having raised a total of $165.3M across 4 funding rounds to date. The company's 1st funding round was a Series B of $51M, raised on Mar 09, 2021.
How many employees does Ventyx Biosciences have?
As of Dec 31, 2024, the latest employee count at Ventyx Biosciences is 82.
What does Ventyx Biosciences do?
Developer of therapeutics to treat autoimmune diseases. The companys pipeline drugs include VTX958 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002 S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735 peripheral inhibitor of the NLRP3 inflammasome. These drugs are used for the treatment of autoimmune disorders by regulating the innate and adaptive immunity to activate type 1 interferon, IL-12, and IL-23 signaling.
Who are the top competitors of Ventyx Biosciences?
What products or services does Ventyx Biosciences offer?
Ventyx Biosciences offers VTX2735, VTX3232, Tamuzimod, and VTX958.
Is Ventyx Biosciences publicly traded?
Yes, Ventyx Biosciences is publicly traded on NASDAQ under the ticker symbol VTYX.
Who are Ventyx Biosciences's investors?
Ventyx Biosciences has 16 investors. Key investors include Lilly, Sanofi, Orbimed, Janus Henderson Investors, and RTW Investments.
What is Ventyx Biosciences's ticker symbol?
The ticker symbol of Ventyx Biosciences is VTYX on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.